Page last updated: 2024-09-03

gefitinib and Diabetic Cardiomyopathies

gefitinib has been researched along with Diabetic Cardiomyopathies in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Akhtar, M; Akhtar, MS; Hassan, MQ; Najmi, AK; Paudel, YN; Shah, S	1

Other Studies

1 other study(ies) available for gefitinib and Diabetic Cardiomyopathies

Article	Year
EGFR tyrosine kinase inhibition decreases cardiac remodeling and SERCA2a/NCX1 depletion in streptozotocin induced cardiomyopathy in C57/BL6 mice. Life sciences, 2018, Oct-01, Volume: 210 Topics: Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; ErbB Receptors; Gefitinib; Mice; Mice, Inbred C57BL; Myocardium; Protein Kinase Inhibitors; Quinazolines; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sodium-Calcium Exchanger	2018

Article

Year

EGFR tyrosine kinase inhibition decreases cardiac remodeling and SERCA2a/NCX1 depletion in streptozotocin induced cardiomyopathy in C57/BL6 mice.

Life sciences, 2018, Oct-01, Volume: 210

Topics: Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; ErbB Receptors; Gefitinib; Mice; Mice, Inbred C57BL; Myocardium; Protein Kinase Inhibitors; Quinazolines; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sodium-Calcium Exchanger

2018